EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy

Alexander D Sherry, Pavlos Msaouel, Zachary R McCaw, Joseph Abi Jaoude, Eric J Hsu, Ramez Kouzy, Roshal Patel, Yumeng Yang, Timothy A Lin, Cullen M Taniguchi, Claus Rödel, Emmanouil Fokas und 6 weitere

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.113357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Alexander D Sherry und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDCR NIH HHS, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The 'Table 1 Fallacy' refers to the unsound use of significance testing for comparing the distributions of baseline variables between randomised groups to draw erroneous conclusions about balance or imbalance. We performed a cross-sectional study of the Table 1 Fallacy in phase III oncology trials. METHODS: From ClinicalTrials.gov, 1877 randomised trials were screened. Multivariable logistic regressions evaluated predictors of the Table 1 Fallacy. RESULTS: A total of 765 randomised controlled trials involving 553,405 patients were analysed. The Table 1 Fallacy was observed in 25% of trials (188 of 765), with 3% of comparisons deemed significant (59 of 2353), approximating the typical 5% type I error assertion probability. Application of trial-level multiplicity corrections reduced the rate of significant findings to 0.3% (six of 2345 tests). Factors associated with lower odds of the Table 1 Fallacy included industry sponsorship (adjusted odds ratio [aOR] 0.29, 95% confidence interval [CI] 0.18-0.47; multiplicity-corrected P < 0.0001), larger trial size (≥795 versus

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansPrevalenceCross-Sectional StudiesRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Covariate imbalanceOncologyPhase IIIRandomised controlled trialsSignificance testing for baseline characteristicsTable 1 FallacyTesting for baseline differences

Autor:innen und Institutionen

  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, Division of Pathology/Lab…
  • Insitro, South San Francisco, CA, USA; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Oncology, Stanford University, Stanford, CA, USA.
  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York,…

Förderung

  • NCI NIH HHS
  • NIDCR NIH HHS
  • NIBIB NIH HHS
  • Andrew Sabin Family Foundation
  • National Institutes of Health
  • Fund for Innovation in Cancer Informatics
  • National Cancer Institute
  • University of Texas MD Anderson Cancer Center

Zitieren

APA

Sherry, A. D., Msaouel, P., McCaw, Z. R., Abi Jaoude, J., Hsu, E. J., Kouzy, R., Patel, R., Yang, Y., Lin, T. A., Taniguchi, C. M., Rödel, C., Fokas, E., Tang, C., Fuller, C. D., Minsky, B., Meirson, T., Sun, R., & Ludmir, E. B. (2023). Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113357

Vancouver

Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, et al. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113357

BibTeX
@article{Sherry2023,
  author = {Sherry, Alexander D and Msaouel, Pavlos and McCaw, Zachary R and Abi Jaoude, Joseph and Hsu, Eric J and Kouzy, Ramez and Patel, Roshal and Yang, Yumeng and Lin, Timothy A and Taniguchi, Cullen M and Rödel, Claus and Fokas, Emmanouil and Tang, Chad and Fuller, Clifton David and Minsky, Bruce and Meirson, Tomer and Sun, Ryan and Ludmir, Ethan B},
  title = {Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.113357}
}
Kostenlos starten →